TLSA Fundamental Analysis - TIZIANA LIFE SCIENCES LTD

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to TLSA. TLSA was compared to 558 industry peers in the Biotechnology industry. While TLSA seems to be doing ok healthwise, there are quite some concerns on its profitability. TLSA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

TLSA had negative earnings in the past year.

In the past year TLSA has reported a negative cash flow from operations.

TLSA had negative earnings in each of the past 5 years.

In the past 5 years TLSA always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of TLSA (-105.13%) is worse than 77.24% of its industry peers.

The Return On Equity of TLSA (-301.40%) is worse than 71.68% of its industry peers.

		Industry Rank	Sector Rank
ROA	-105.13%
ROE	-301.4%
ROIC	N/A

ROA(3y)-83.77%

ROA(5y)-135.3%

ROE(3y)-151.66%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TLSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, TLSA has more shares outstanding

TLSA has more shares outstanding than it did 5 years ago.

TLSA has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 6.68 indicates that TLSA is not in any danger for bankruptcy at the moment.

TLSA has a better Altman-Z score (6.68) than 81.36% of its industry peers.

There is no outstanding debt for TLSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	6.68

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 1.02 indicates that TLSA should not have too much problems paying its short term obligations.

TLSA's Current ratio of 1.02 is on the low side compared to the rest of the industry. TLSA is outperformed by 87.28% of its industry peers.

TLSA has a Quick Ratio of 1.02. This is a normal value and indicates that TLSA is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 1.02, TLSA is doing worse than 86.20% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.02
Quick Ratio	1.02

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TLSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.02%, which is quite impressive.

EPS 1Y (TTM)36.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%26.02%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TLSA will show a small growth in Earnings Per Share. The EPS will grow by 3.28% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y13.33%

EPS Next 2Y3.28%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLSA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLSA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y3.28%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TLSA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TIZIANA LIFE SCIENCES LTD

NASDAQ:TLSA (7/14/2025, 8:08:20 PM)

After market: 1.5496 +0.07 (+4.7%)

1.48

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)07-01 2025-07-01/amc

Earnings (Next)10-13 2025-10-13

Inst Owners2.73%

Inst Owner Change0%

Ins Owners37.72%

Ins Owner ChangeN/A

Market Cap164.96M

Analysts82.86

Price TargetN/A

Short Float %0.75%

Short Ratio1.46

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	41.91
P/tB	41.91
EV/EBITDA	N/A

EPS(TTM)-0.11

EYN/A

EPS(NY)-0.14

Fwd EYN/A

FCF(TTM)-0.14

FCFYN/A

OCF(TTM)-0.14

OCFYN/A

SpS0

BVpS0.04

TBVpS0.04

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-105.13%
ROE	-301.4%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-83.77%

ROA(5y)-135.3%

ROE(3y)-151.66%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.02
Quick Ratio	1.02
Altman-Z	6.68

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)36.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%26.02%

EPS Next Y13.33%

EPS Next 2Y3.28%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y12.18%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y19.99%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y19.99%

OCF growth 3YN/A

OCF growth 5YN/A

TIZIANA LIFE SCIENCES LTD (TLSA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens